Caris Life Sciences stock falls after hours despite Q3 beat, BTIG maintains buy

Caris Life Sciences (NASDAQ:CAI) shares fell 13% after hours despite Q3 revenue beat of $275.4M (up 27% YoY) and raised guidance. BTIG maintains a Buy rating and $38 target, citing strong growth but noting concerns over Q4 2026 guidance. The company plans to launch a new test in December. Adjusted earnings missed at $0.05 per share vs. $0.16 expected.

Original reporting
Published Nov 5, 2026, 11:20 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 11:43 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$CAI
Bearish
high confidence
Mentioned
$CAI
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$CAIBearishMed
01

Why it matters

The earnings miss and cautious Q4 guidance triggered a sharp after‑hours sell‑off, but analyst support remains, creating a potential short‑term entry point.

02

Market read

The report provides fresh earnings data and guidance for CAI, influencing short‑term price action and offering a potential trade signal.

03

What to watch

Strong revenue growth and new test launches could support longer‑term upside despite short‑term miss.

Relevance 7/10Novelty 7/10Timing: after‑hours today

Background

Caris Life Sciences is a precision oncology diagnostics company that recently launched new sequencing‑based tests.

Company-level read

Ticker impact

$CAIBearishHigh confidence
Context

Caris Life Sciences reported Q3 earnings that beat revenue expectations but missed EPS, prompting a 13% after‑hours price drop despite a BTIG buy rating.

Expected impact

downward pressure as the market prices in the earnings miss and cautious guidance

Evidence & confidence

The stock fell 13% in after‑hours despite a beat, indicating traders view the miss and guidance as a near‑term downside catalyst.

Market effects

Precision oncology diagnostics may face heightened scrutiny on guidance guidance, affecting peers.

US biotech sector may see modest pullback as earnings miss spreads.

Limited; impact confined to US biotech and related investors.

Counterpoint

BTIG maintains a buy rating and a $38 target, suggesting the dip may be an overreaction and a buying opportunity.

Key entities

  • BTIG

    Maintained buy rating and $38 price target.

  • TD Cowen

    Raised price target to $38.

Related articles

$CAIMed

Caris Life Sciences Inc (CAI) Q3 2026 Earnings Call Highlights: Record Revenue, Sixth

Caris Life Sciences (CAI) reported Q3 2026 revenue growth, but faced negative free cash flow of $39.7M due to capital expenditures. Operating expenses rose $48.1M year-over-year, and full-year GAAP opex guidance was raised to ~$620M. New product launches without reimbursement may pressure margins. Q4 pharma R&D services revenue is expected to decline sequentially. The company is expanding its commercial team and expects positive free cash flow in Q4.

$CAIHigh

Caris Life (CAI) Q3 2026 Earnings Call Transcript

Caris Life (CAI) reported Q3 2026 earnings, highlighting 21% year-over-year clinical case growth and 27% revenue increase to $275M. The company launched new products, including Caris Assure for monitoring and plans to launch Caris Confirm for MRD in December. Caris Detect, their early-stage cancer detection test, is gaining market traction. The company maintained profitability with adjusted EBITDA of $44.4M and net income of $15.3M.

$CAIMed

TD Cowen raises Caris Life Sciences stock price target on pipeline

TD Cowen raised its price target for Caris Life Sciences (CAI) to $38 from $36, maintaining a Buy rating. The company reported Q3 sales beating expectations by 9%, with revenue up 85% year-over-year and a 70% gross margin. Despite this, shares fell 15% post-market due to an earnings miss. The stock has gained 65% since pre-Q2 levels, but InvestingPro suggests it may be overvalued.

$CAIMed

Caris Life Sciences Q3 Earnings Call Highlights

Caris Life Sciences reported Q3 net income of $15.3M, down from $24.3M YoY, with adjusted EBITDA at $44.4M. Operating expenses rose to $163M, and full-year expense forecast increased to $620M. Free cash flow was negative $39.7M. The company launched new cancer-detection tests and plans to introduce them selectively. Caris Detect, a multi-cancer early detection test, is being marketed with campaigns and partnerships. The company has 325 commercial team members and plans to expand further.